Biote Corp. Class A Common Stock earnings per share and revenue
On Mar 11, 2026, BTMD reported earnings of 0.06 USD per share (EPS) for Q4 25, beating the estimate of 0.05 USD, resulting in a 17.65% surprise. Revenue reached 46.41 million, compared to an expected 47.11 million, with a -1.50% difference. The market reacted with a -10.47% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 5 analysts forecast an EPS of 0.04 USD, with revenue projected to reach 46.94 million USD, implying an decrease of -33.33% EPS, and increase of 1.15% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Omeros Corporation
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.58
Actual
$0.98
Surprise
+268.56%
Tilray Brands, Inc. Common Stock
Report Date
Apr 01, 2026 For Q3 26
Estimate
-$0.14
Actual
-$0.24
Surprise
-68.07%
FitLife Brands, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
$0.21
Actual
$0.16
Surprise
-25.22%
Neogen Corp
Report Date
Apr 09, 2026 For Q3 26
Estimate
$0.05
Actual
$0.09
Surprise
+53.32%
IM Cannabis Corp. Common Shares
Report Date
Mar 30, 2026 For Q4 25
Estimate
$0.12
Actual
-$1.19
Surprise
-1055.53%
FAQ
What were Biote Corp. Class A Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Biote Corp. Class A Common Stock reported EPS of $0.06, beating estimates by 17.65%, and revenue of $46.41M, -1.5% below expectations.
How did the market react to Biote Corp. Class A Common Stock's Q4 2025 earnings?
The stock price moved down -10.47%, changed from $1.72 before the earnings release to $1.54 the day after.
When is Biote Corp. Class A Common Stock expected to report next?
The next earning report is scheduled for May 05, 2026.
What are the forecasts for Biote Corp. Class A Common Stock's next earnings report?
Based on 5
analysts, Biote Corp. Class A Common Stock is expected to report EPS of $0.04 and revenue of $46.94M for Q1 2026.